I know I've said this before, but once again I don't think that DM is the issue here. I'm not defending him for any particular reason other than that now I think it's bigger than just him.  He may still be the front man for RVX but he's not making any of the current decisions in isolation.  For the company to post their development plan as detailed in option 1 on their website in that degree of detail is telling.  And, although I did not hear DMs presentation the other day someone said that the tone of his presentation sounded like things were close to being a done deal.  My point is that just because there have been disappointments in the past doesn't mean that will always be so.  The glass need not always be half empty.

The detail provided in option one states that 'our new partner can supply THEIR SGLT2 diabetes drug as the co-medication.  So, who are the primary manufacturers of SGLT2 inhibitors?  BI?  Eli Lilly?  Both of these companies have already been mentioned by name by RVX in a previous PR earlier this year.  I think it was Eli Lilly that would see their patent expire in the not too distant future. So, maybe it's Eli Lilly??  $140B market cap.....you tell me it isn't possible.

A confirmed BTD and FDA buy-in to a follow-up and potentially accelerated P3 trial; and, a high likelihood of a BP partner announcement in the next 12 weeks.  Are these not good things??? 

After the disappointment of what happened last September, I'm failing to see the big downside here. I think DM will ride (somewhat) into the sunset (sometime) after this deal is formally announced.  To see him go prior to the announcement of this deal would not be fair or honouring to him given the 20 years he has invested in this company......IMO.

So, let's see what happens in the next couple of months.  If it all turns out to be the nothingbuger that some of you think then I won't be joining you in doing any online bashing simply because, like many of you, I'll be gone.